Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MIMP (micro integral membrane protein) is a protein derived from Lactobacillus plantarum. It is being investigated for its role in protecting the intestinal barrier from injury and reducing intestinal permeability. Its mechanism of action involves inhibiting zonulin, a protein that regulates intestinal permeability, and this inhibition is further regulated by microRNA-122a. MIMP also enhances the expression and distribution of tight junction proteins, modulates inflammatory cytokines by decreasing pro-inflammatory and increasing anti-inflammatory cytokines, and influences the gut microbiota. Additionally, it has been shown to modulate the Toll-like receptor 4 pathway and histone acetylation, and binds to DC-SIGN on dendritic cells to induce anti-inflammatory responses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MIMP.